Streetbeat News

Outset Medical, Inc.

https://www.outsetmedical.com

Industry

Medical - Devices

Outset Medical, Inc., a medical technology company, develops a hemodialysis system for dialysis. It provides the Tablo Hemodialysis System, which comprises a compact console with integrated water purification, on-demand dialysate production, and software and connectivity capabilities for dialysis care in acute and home settings. The company was formerly known as Home Dialysis Plus, Ltd. and changed its name to Outset Medical, Inc. in January 2015. Outset Medical, Inc. was incorporated in 2003 and is headquartered in San Jose, California.

Open

0.85

Mkt cap

42M

Volume

641K

High

0.86

P/E Ratio

-0.29

52-wk high

6.37

Low

0.78

Div yield

N/A

52-wk low

0.43

Outset Medical, Inc. will present at the 2024 Stifel Healthcare Conference, showcasing their innovative dialysis technology.

Portfolio Pulse from

November 15, 2024 | 2:15 pm

Outset Medical Inc. held its Q3 2024 earnings call, discussing financial results and company performance. Key participants included company executives and analysts from various financial institutions.

Portfolio Pulse from

November 07, 2024 | 2:45 pm

Outset Medical, Inc. (OM) reported a Q3 loss of $0.39 per share, which was better than the Zacks Consensus Estimate of a $0.42 loss. This is an improvement from the $0.71 loss per share reported a year ago.

Portfolio Pulse from

November 06, 2024 | 11:45 pm

Outset Medical, Inc. (Nasdaq: OM) reported its financial results for the third quarter of 2024, highlighting its innovative technology aimed at reducing dialysis costs and complexity.

Portfolio Pulse from

November 06, 2024 | 9:15 pm

Outset Medical Inc received a notice from Nasdaq on September 23 for failing to satisfy a continued listing rule or standard.

Portfolio Pulse from Benzinga Newsdesk

September 27, 2024 | 8:12 pm

RBC Capital has downgraded Outset Medical (NASDAQ:OM) from Outperform to Sector Perform and lowered its price target from $6 to $3.

Portfolio Pulse from Benzinga Newsdesk

August 08, 2024 | 7:39 pm

U.S. stocks traded higher with significant gains in the Nasdaq Composite, Dow, and S&P 500. US Foods Holding Corp. reported better-than-expected sales, while XPEL, Viasat, and GSE Systems saw substantial stock price increases. Conversely, Cardlytics, Outset Medical, and Bumble experienced significant declines due to poor financial results.

Portfolio Pulse from Avi Kapoor

August 08, 2024 | 6:49 pm

TD Cowen analyst Joshua Jennings maintains a Buy rating on Outset Medical (NASDAQ:OM) but lowers the price target from $9 to $3.

Portfolio Pulse from Benzinga Newsdesk

August 08, 2024 | 6:09 pm

U.S. stocks surged with the Dow Jones gaining over 500 points. Eli Lilly reported strong Q2 earnings and raised its full-year guidance. XPEL, Viasat, and GSE Systems saw significant stock price increases due to positive earnings and acquisition news, while Cardlytics, Outset Medical, and Bumble experienced sharp declines following disappointing earnings.

Portfolio Pulse from Avi Kapoor

August 08, 2024 | 4:06 pm

Outset Medical shares are trading lower after the company reported worse-than-expected Q2 financial results and cut its FY24 revenue guidance.

Portfolio Pulse from Benzinga Newsdesk

August 08, 2024 | 11:39 am

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.